CG Oncology, Inc.

Historical 13F Holders

Symbol
CGON
CUSIP
156944100
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 156944100 since 12/18/2024, newest first.

Filer % of Class Filed
RTW Investments, LP 13G/A Amendment 1
9.7% 8/14/2026
Event 6/30/2026
Foresite Capital Fund V, L.P. 13G/A Amendment 1
4.9% 8/14/2026
Event 6/30/2026
Wellington Management Group LLP 13G/A Amendment 1
6.0% 8/13/2026
Event 6/30/2026
BlackRock, Inc. 13G/A Amendment 1 6.8% 7/27/2026
Event 6/30/2026
T. Rowe Price Investment Management, Inc. 13G 8.0% 5/15/2026
Event 3/31/2026
RTW Investments, LP 13G
8.3% 5/15/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 3 0% 3/26/2026
Event 3/13/2026
Wellington Management Group LLP 13G
7.2% 11/12/2025
Event 9/30/2025
Vanguard Group Inc 13G/A Amendment 2 8.6% 10/30/2025
Event 9/30/2025
Seven Fleet Capital Management LP 13D/A Amendment 1
2.0% 10/28/2025
Event 10/6/2025
Longitude Capital Partners IV, LLC 13D
6.0% 9/18/2025
Event 9/11/2025
Seven Fleet Partners LP 13D
2.0% 9/18/2025
Event 9/11/2025
FMR LLC 13G
5.1% 8/6/2025
Event 6/30/2025
TCG Crossover GP I, LLC 13G/A Amendment 1
4.8% 5/15/2025
Event 3/31/2025
Decheng Capital Global Life Sciences Fund IV, L.P. 13G/A Amendment 2
8.4% 2/14/2025
Event 12/31/2024
Unique Diamond Investments Ltd 13G/A Amendment 1
5.5% 1/28/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 15 107 k $7.50 M
2026 Q2 247 97.9 M $6.72 B
2026 Q1 251 88.3 M $5.94 B
2025 Q4 209 82.7 M $3.43 B
2025 Q3 188 78.4 M $3.16 B
2025 Q2 173 76.0 M $1.97 B
2025 Q1 148 70.8 M $1.74 B
2024 Q4 147 67.4 M $1.93 B
2024 Q3 126 52.2 M $1.96 B
2024 Q2 116 43.4 M $1.37 B
2024 Q1 101 38.9 M $1.71 B